{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 2 study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-2-study-of-fianlimab-cemiplimab-and-ipilimumab-in-anti-pd-1-refractory-melanoma\/#breadcrumbitem"}]}